2240 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 7
Lehmann et al.
force field as implemented in MOE, version 2005.06.38 Conforma-
tions with energies above 3 kcal/mol from the global minimum
were discarded, and the remaining ones were manually superim-
posed. Each overlap was refined using the flexible alignment
module in MOE and ranked by the values of conformational energy.
(17) Affolter, J.; Webb, D. J. Urotensin II: a new mediator in cardio-
pulmonary regulation? Lancet 2001, 358, 774-775.
(18) Jin, J.; Dhanak, D.; Knight, S. D.; Widdowson, K.; Aiyar, N.;
Naselsky, D.; Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Bennett, C.
D. Wang, B.; Warren, G. L.; Moore, M. L.; Keenan, R. M.; Rivero,
R. A.; Douglas, S. A. Aminoalkoxybenzyl pyrrolidines as novel
human urotensin-II receptor antagonists. Bioorg. Med. Chem. Lett.
2005, 15, 3229-3232.
Acknowledgment. Financial support was obtained from The
Knut and Alice Wallenberg Foundation and The Swedish
Research Council.
(19) Lehmann, F.; Currier, E. A.; Olsson, R.; Hacksell, U.; Luthman, K.
Isochromanone-based urotensin-II receptor agonists. Bioorg. Med.
Chem. 2005, 13, 3057-3068.
(20) Croston, G. E.; Olsson, R.; Currier, E. A.; Burstein, E. S.; Weiner,
D.; Nash, N.; Severance, D.; Allenmark, S. G.; Thunberg, L.; Ma, J.
N.; Mohell, N.; O’Dowd, B.; Brann, M. R.; Hacksell, U. Discovery
of the first nonpeptide agonist of the GPR14/urotensin-II receptor:
3-(4-chloropheny)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-
7954). J. Med. Chem. 2002, 45, 4950-4953.
(21) Bandini, M.; Cozzi, P. G.; Gazzano, M.; Umani-Ronchi, A. An
effective and useful synthesis of enantiomerically enriched arylgly-
cinols. Eur. J. Org. Chem. 2001, 1937-1942.
Supporting Information Available: Elemental analysis and 1H
and 13C NMR spectral data for all synthesized compounds. Synthetic
procedures, compound characterizations, and results from in vitro
testing of UII receptor affinity of the ester derivatives 4f-4bb. A
table of crystal data and structure refinement for compound (+)-5l
HCl. This material is available free of charge via the Internet at
(22) Ritter, J. J.; Minieri, P. P. A new reaction of nitriles. 1. Amides from
alkenes and mononitriles. J. Am. Chem. Soc. 1948, 70, 4045-4048.
(23) When using triethylamine as the base, the quaternary ammonium
compound was the major product. The use of DIPEA as the base
solved this problem, but made the purification of the products more
difficult.
(24) Other coupling reagents were also examined; with DCC the formation
of product proceeded smoothly, but the products were difficult to
purify from the DCU byproduct. When using acid chlorides, more
complex mixtures were formed.
(25) Takami, A.; Iwakubo, M.; Okada, Y.; Kawata, T.; Odai, H.;
Takahashi, N.; Shindo, K.; Kimura, K.; Tagami, Y.; Miyake, M.;
Fukushima, K.; Inagaki, M.; Amano, M.; Kaibuchi, K.; Iijima, H.
Design and synthesis of Rho kinase inhibitors (I). Bioorg. Med. Chem.
2004, 12, 2115-2137.
(26) Bra¨uner-Osborne, H.; Brann, M. R. Pharmacology of muscarinic
acetylcholine receptor subtypes (m1-m5): High throughput assays
in mammalian cells. Eur. J. Pharmacol. 1996, 295, 93-102.
(27) Burstein, E. S.; Bra¨uner-Osborne, H.; Spalding, T. A.; Conklin, B.
R.; Brann, M. R. Interactions of muscarinic receptors with the
heterotrimeric G proteins G(q) and G(12): Transduction of prolifera-
tive signals. J. Neurochem. 1997, 68, 525-533.
(28) Burstein, E. S.; Spalding, T. A.; Brann, M. R. Pharmacology of
muscarinic receptor subtypes constitutively activated by G proteins.
Mol. Pharmacol. 1997, 51, 312-319.
(29) Spalding, T. A.; Burstein, E. S.; Jorgensen, H. B.; Hilleubanks, D.;
Brann, M. R. Pharmacology of a constitutively activated M5
muscarinic receptor. Life Sci. 1995, 56, 1021-1021.
(30) An additional set of ester derivatives has been synthesized and tested
(4f-4bb). The results are presented in the Supporting Information.
(31) Crystallographic data (excluding structure factors) for (+)-5l HCl
has been deposited with the Cambridge Crystallographic Data Centre
as supplementary publication Nos. CCDC 272185. Copies of the data
can be obtained, free of charge, on application to CCDC, 12 Union
Rd., Cambridge CB2 1EZ, UK, (fax: +44 1223 336033 or e-mail:
deposit@ccdc.cam.ac.uk).
References
(1) Dhanak, D.; Neeb, M. J.; Douglas, S. A. Urotensin-II receptor
modulators. Annu. Rep. Med. Chem. 2003, 38, 99-110.
(2) Doggrell, S. A. Urotensin-II and the cardiovascular system - the
importance of developing modulators. Expert Opin. InVest. Drug
2004, 13, 479-487.
(3) Douglas, S.; Dhanak, D.; Johns, D. G. From ‘gills to pills’: urotensin
II as a regulator of mammalian cardiorenal function. Trends Phar-
macol. Sci. 2004, 25, 76-85.
(4) Douglas, S. A. Human urotensin-II as a novel cardiovascular target:
‘heart’ of the matter or simply a fishy ‘tail’? Curr. Opin. Pharmacol.
2003, 3, 159-167.
(5) Onan, D.; Hannan, R. D.; Thomas, W. G. Urotensin II: the old kid
in town. Trends Endocrinol. Metab. 2004, 15, 175-182.
(6) Ong, K. L.; Lam, K. S. L.; Cheung, B. M. Y. Urotensin II: Its
function in health and its role in disease. CardioVasc. Drug Ther.
2005, 19, 65-75.
(7) Russell, F. D. Emerging roles of urotensin-II in cardiovascular disease.
Pharmacol. Ther. 2004, 103, 223-243.
(8) Thanassoulis, G.; Huyhn, T.; Giaid, A. Urotensin II and cardiovas-
cular diseases. Peptides 2004, 25, 1789-1794.
(9) Heringlake, M.; Kox, T.; Uzun, O.; Will, B.; Bahlmann, L.; Klaus,
S.; Eleftheriadis, S.; Armbruster, F. P.; Franz, N.; Kraatz, E. The
relationship between urotensin II plasma immunoreactivity and left
ventricular filling pressures in coronary artery disease. Regul. Pept.
2004, 121, 129-136.
(10) Douglas, S.; Aiyar, N. V.; Ohlstein, E. H.; Willette, R. N. Human
urotensin-II, the most potent mammalian vasoconstrictor identified,
represents a novel therapeutic target in the treatment of cardiovascular
disease. Eur. Heart J. 2000, 21, 229-237.
(11) Bousette, N.; Patel, L.; Douglas, S. A.; Ohlstein, E. H.; Giaid, A.
Increased expression of urotensin II and its cognate receptor GPR14
in atherosclerotic lesions of the human aorta. Atherosclerosis 2004,
176, 117-123.
(12) Langham, R. G.; Kelly, D. J.; Gow, R. M.; Zhang, Y.; Dowling, J.
K.; Thomson, N. M.; Gilbert, R. E. Increased expression of urotensin
II and urotensin II receptor in human diabetic nephropathy. Am. J.
Kidney Dis. 2004, 44, 826-831.
(32) Håkansson, M. Labile copper(I) chloride complexes: preparation and
handling. Inorg. Synth. 1998, 32, 222-228.
(33) Rigaku, CrystalClear, version 1.3, 2000, Rigaku Corporation, Tokyo,
Japan.
(34) Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. Comple-
tion and refinement of crystal structures with Sir92. J. Appl.
Crystallogr. 1993, 26, 343-350.
(13) Suzuki, S.; Zong, W. Y.; Hirai, M.; Hinokio, Y.; Suzuki, C.; Yamada,
T.; Yoshizumi, S.; Suzuki, M.; Tanizawa, Y.; Matsutani, A.; Oka,
Y. Genetic variations at urotensin II and urotensin II receptor genes
and risk of type 2 diabetes mellitus in Japanese. Peptides 2004, 25,
1803-1808.
(14) Guerrini, R.; Camarda, V.; Marzola, E.; Arduin, M.; Calo, G.;
Spagnol, M.; Rizzi, A.; Salvadori, S.; Regoli, D. Structure-activity
relationship study on human urotensin II. J. Pept. Sci. 2005, 11, 85-
90.
(15) Grieco, P.; Rovero, P.; Novellino, E. Recent structure-activity studies
of the peptide hormone urotensin-II, a potent vasoconstrictor. Curr.
Med. Chem. 2004, 11, 969-979.
(16) Lavecchia, A.; Cosconati, S.; Novellino, E. Architecture of the human
urotensin II receptor: Comparison of the binding domains of peptide
and non-peptide urotensin II agonists. J. Med. Chem. 2005, 48, 2480-
2492.
(35) Sheldrick, G. M., University of Go¨ttingen, Germany, 1997.
(36) Farrugia, L. J. WinGX suite for small-molecule single-crystal
crystallography. J. Appl. Crystallogr. 1999, 32, 837-838.
(37) Farrugia, L. J. ORTEP-3 for Windows - a version of ORTEP-III
with a Graphical User Interface (GUI). J. Appl. Crystallogr. 1997,
30.
(38) MOETM, the Molecular Operating Environment by Chemical
Computing Group, Suite 910-1010 Sherbrooke St., W Montreal,
Quebec, Canada H3A 2R7.
JM051121I